BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Visugromab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Visugromab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04725474-2796@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Visugromab: Phase 1/2 readout est. (NCT04725474)
DESCRIPTION:Visugromab\, phase 1/2.\nStudy: First-in-Human Study of the GDF
 -15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced C
 ancer (GDFATHER)\nEstimated primary completion: 30 April 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/visugromab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04725474
URL:https://assetmemo.bio/drug/visugromab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07098988-2796@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Visugromab: Phase 2 readout est. (NCT07098988)
DESCRIPTION:Visugromab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tria
 l Investigating Visugromab in Combination With Immunochemotherapy in 1L Tr
 eatment of Participants With Metastatic NSCLC\nEstimated primary completio
 n: 31 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vis
 ugromab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07098988
URL:https://assetmemo.bio/drug/visugromab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219459-2796@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Visugromab: Phase 2 readout est. (NCT07219459)
DESCRIPTION:Visugromab\, phase 2.\nStudy: Visugromab\, Nivolumab and Lenvat
 inib Compared to Double Placebo and Lenvatinib in Unresectable or Metastat
 ic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure\nEstimated primary c
 ompletion: September 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/visugromab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07219459
URL:https://assetmemo.bio/drug/visugromab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07246863-2796@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Visugromab: Phase 2 readout est. (NCT07246863)
DESCRIPTION:Visugromab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tria
 l Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L T
 reatment of Participants With Metastatic NSCLC\nEstimated primary completi
 on: 1 October 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/v
 isugromab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07246863
URL:https://assetmemo.bio/drug/visugromab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07112196-2796@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Visugromab: Phase 2/3 readout est. (NCT07112196)
DESCRIPTION:Visugromab\, phase 2/3.\nStudy: Visugromab in Cachexia Internat
 ional Trial\nEstimated primary completion: December 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/visugromab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07112196
URL:https://assetmemo.bio/drug/visugromab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
